H
IGHLY purified interleukin-2 (IL-2) expressing the gene for IL-2 in Escherichia coli (clone) is now available through recombinant deoxyribonucleic acid (DNA) technology.~-"24 Recombinant IL-2 (rlL-2) has been shown to possess a broad range of immunoregulatory activities, and the in vivo administration of rIL-2 has been reported to be capable of enhancing the antitumor activity of adoptive transfer of immune lymphocytes expanded in IL-2. 'j'13"2~ 25-27.3 , On the other hand, recent preliminary clinical and animal trials have shown that systemic infusion of high-dose rIL-2 may produce toxic side effects such as pulmonary and hemodynamic abnormalities and neurological dysfunction. 4''5-2~ The causative mechanisms have not been clarified, although they appear to be directly related to systemic capillary permeability. It has recently been suggested in animal models that, following systemic high-dose injection of rlL-2, brain vascular permeability is also increased, accompanied by profound morphological vasculature and parenchymal change) Furthermore, it has been reported that in two of 12 patients without central nervous system disease (with intact blood-brain barrier (BBB)), barrier disruption followed systemic administration of rlL-2, probably related to increased vascular permeability in the normal brain? ~ It is not known, however, whether direct intracerebral injection of rlL-2 affects neuronal or glial cells of normal brain. In addition to histological changes, there remain other very important problems that should be resolved; these include the possibility of IL-2 receptor (IL-2R) being induced on the cell surface of normal brain tissue and of antibodies formed against IL-2 being produced after direct intracerebral injection of rlL-2.
Effects of intracerebral injection of IL-2 in mice
The aim of the present study was to examine whether pathological changes and anti-IL-2 antibodies are produced after single or repeated injections of rlL-2 into a normal adult mouse brain. Furthermore, the expression of IL-2R on the cell surface of brain tissue was ascertained before and after intracerebral injection of rlL-2, using immunofluorescence techniques with monoclonal antibody (MAb) against mouse IL-2R. The possibility of clinical application of rlL-2 for brain tumors is also discussed.
Materials and Methods

Preparations
Male 6-to 8-week-old C57BL/6 mice were supplied from the Animal Center of Kyoto University for all experiments. Highly purified rIL-2 (TGP-3) derived from Escherichia coli and purified to homogeneity was used.* The rIL-2 had a specific activity of 3.5 x 10 4 U/rag protein in Takeda units. ~2' 33 It corresponded to 1.2 • 10 7 U/mg protein, calculated on the basis of the Biological Response Modifiers Program reference reagent human IL-2 (Jurkat). 8 After lyophilization and reconstitution with phosphate-buffered saline (PBS) (0.02 M sodium phosphate buffer, pH 7.0, containing 0.15% NaC1), the rIL-2 was given as an intracerebral or intraperitoneal infusion. The level of endotoxin in the preparation was less than 0.1 ng/mg of rIL-2 as measured in a standard Limulus amebocyte lysate assay.
For the lymphocyte preparation, mesenteric lymph node cells from normal adult mice were prepared by dispersing the cells with scissors. The lymphoid cells were suspended at 5 • 106/ml in RPMI-1640 medium supplemented with 2% heat-inactivated fetal calf serum (FCS) and concanavalin A (5 ~g/ml),t and cultured at 37~ for 3 days in an atmosphere of 95% air and 5% CO2. The mitogen-activated lymphocytes were used as a positive control for immunohistochemical staining of IL-2R.
Intracerebral Injection of IL-2
The reconstituted rlL-2 was injected into the fight cerebral hemisphere of adult mice with a 25-ul Hamilton microinjector and a Yaoi needle. The intracerebral injection point was performed under semi-stereotactical guidance, 5 mm to the fight of the midline and 5 mm posterior to the midorbital line. The injected mice were divided into three groups according to the dose of administered rIL-2 titer: 8, 32, or 80 U. These three groups were further divided into two subgroups each, one receiving single and the other multiple (serial 4-weekly) injections of rIL-2. The volume of the intracerebral injection was kept less than 10 ul per mouse in order to avoid the production of increased intracranial pressure. 34 Mouse albumin was purified by gel filtration * Recombinant IL-2 kindly supplied by Takeda Chemical Industries, Ltd., Osaka, Japan.
~-Concanavalin A supplied by Pharmacia Fine Chemicals, AB Uppsala, Sweden.
(Sephadex G-200) and successive ion exchange chromatography (diethylaminoethyl cellulose). The purified mouse albumin was adjusted to the same concentration of protein as rlL-2 in each group of the injected mice, when used as a sham control preparation for intracerebral administration of rlL-2. For systemic administration of rlL-2 as a control, reconstituted rlL-2 was injected intraperitoneally at the same time as the intracerebral injection.
After rlL-2 administration, IL-2 and anti-IL-2 antibody activity in the serum and histological examination including IL-2R expression were chronologically investigated in each group of treated mice. Groups of three to 10 adult mice were used for each experiment.
Antisera
In order to obtain both IL-2-specific capture antibody and indicator antibody for determination of IL-2 activity by enzyme immunoassay (EIA) using a double-antibody sandwich, rlL-2 (1 mg/ml in PBS) was emulsified in an equal volume of Freund's complete adjuvant,z~ and an aliquot containing 1.0 mg of rlL-2 was given subcutaneously to goat and rabbit. Antisera were collected after successive 3-weekly injections of rlL-2 emulsified with incomplete Freund's adjuvant. For purification of anti-IL-2 antisera, immunoglobulin was precipitated with (NH4)2504 at 40% saturation. After dialysis, specific antibodies were isolated by affinity chromatography on rlL-2-Sepharose 4B. Affinity-purified antisera were prepared by adsorption of hyperimmunized antisera on Sepharose 4B columns with the antigen (rlL-2) covalently linked with subsequent elution. The titer of each serum was then measured by EIA. The eluate containing immunoglobulin was neutralized to pH 7.0 with NaOH and frozen until use. Goat anti-IL-2 antibody was used as IL-2-specific capture antibody. Rabbit anti-IL-2 antibody was used as indicator antibody, and was labeled directly with horseradish peroxidase. 1~ In order to obtain the standard positive control with definite IL-2 neutralizing activity, mice were immunized subcutaneously with 0.2 mg of TGP-3 emulsified with complete Freund's adjuvant. Antisera were collected after successive 3-weekly injections of TGP-3 emulsified with incomplete Freund's adjuvant. The titer of each serum was measured by enzyme-linked immunosorbent assay (ELISA) after purification by affinity chromatography on rlL-2-Sephadex 4B.
For immunohistochemical analysis of IL-2R, rat anti-mouse IL-2R MAb was used.w
Measurement of lL-2 Activity
Two assay procedures were used for IL-2 activity in serum. A conventional bioassay for IL-2 and a double antibody sandwich EIA in which a solid phase is coated with IL-2-specific antibody. For bioassay, IL-2 activity was evaluated by its ability to maintain an IL-2-dependent murine cell line, as reported previously. ~' 333~' In the present study, however, the double antibody method was used exclusively because the latter method showed much higher sensitivity and absolute specificity for IL-2. TM A solid phase is coated with IL-2-specific capture antibody. This is reacted with the test sample containing IL-2, then with enzyme-labeled IL-2-specific indicator antibody constituting a different species from the capture antibody, followed by the enzyme substrate. The antigen (or IL-2) in the test sample is captured and immobilized on the sensitized solid phase where it can itself then fix the enzyme-labeled antibody. The microtiter plates were precoated with the capture antibody by incubating them overnight at room temperature with a solution of antibody in 0.1 M PBS (100 tzl/well at 15 izg/ml). The optimum concentrations of capture antibody were determined by titration. After two washes with PBS, 100 #1 of 5% serum in PBS was added to each well for 1 hour to block nonspecific binding during subsequent steps. The serum used in this step and in the diluent for subsequent steps was from the same species of animal as the indicator antibody. Two washes with PBS were followed by the addition (100 ul/well) of the serially diluted test samples, of a positive control solution (10% rlL-2 diluted in newborn calf serum) and a negative control solution (newborn calf serum alone diluted in PBS). After incubation at room temperature for 90 minutes the plates were washed five times with PBS, and then indicator antibody at a dilution of 1:1000 in PBS was added to each well (100 #1/ well). A further 90 minutes of incubation followed, then the plates were washed five times with PBS. The amount of IL-2 bound was then detected by the addition of 100 tA of substrate solution containing 0.2% of O-phenylenediamine, 6 mM H~O~, and 0.01% thimerosal in 0.1 M phosphate-citrate buffer, pH 5.0. These wells were incubated at room temperature for 10 minutes. The reaction was stopped by the addition of 4 M H2504. Absorbance (optical density value) was measured by spectrophotometry at a wavelength of 492 nm. The results generated in this assay were evaluated by the ratio of the optical densities of test sample to a group of known reference negative and positive control samples.
Measurement of Anti-IL-2 Antibody Activity
The anti-IL-2 antibody activity of test samples was determined at serial dilutions run in duplicate by an ELISA. The microtiter plates were coated by incubation for 2 days at 4~ with a solution of TGP-3 in 0.01 M Na2HPO4 and 0.01 M NaCI, pH 8.0 (100 #l/well at 10 t~g/ml). After two washes with PBS, 100 ul of 2% bovine serum albumin in PBS was added to each well. The wells were incubated overnight at 4"C to block nonspecific binding during subsequent steps. A 250-ul aliquot of the serially diluted test sample in RPMI-1640 me-
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dium containing 10% heat-inactivated FCS was added to the precoated microtiter plates with TGP-3 and incubated overnight at room temperature. After the solution was decanted, the wells were rinsed five times with RPMI-1640 medium containing 10% FCS. A 100-ul aliquot of 5000-fold diluted horseradish peroxidaseconjugated rabbit anti-mouse immunoglobulin (Ig)M and IgG (Fab fragment) was added to each well and incubated at room temperature for 3 hours. After this solution was decanted, the wells were rinsed six times with PBS. The amount of anti-IL-2 antibody bound was then detected by the addition of 100 ul of substrate solution containing 0.2% of O-phenylenediamine, 6 mM H20:, and 0.01% thimerosal in 0.1 M phosphatecitrate buffer, pH 5.0. These wells were incubated at room temperature for 10 minutes. The reaction was stopped by the addition of 4 M HzSO4. Absorbance (optical density value) was measured by spectrophotometry at a wavelength of 492 nm.
When the titer of anti-IL-2 antibody activity in test samples was determined, both positive (mouse antiserum with definite IL-2 neutralizing activity) and negative (serum from normal mice) controls were simultaneously tested at serial fourfold dilutions at between 1:4 and 1:4096. The results generated in this assay were evaluated by the ratio of the optical densities of the test sample to a group of known reference negative and positive control samples. The titer of anti-IL-2 antibody activity in test samples was then calculated by the reciprocal of dilution at which the test sample shows more than twofold optical densities of the reference negative samples. The protein concentrations were calculated by reference to a semilogarithmic standard curve derived from nine dilutions of mouse IgG (Fig. 1) .
Histological Study
Parallel experiments of mice treated with rIL-2 and purified mouse albumin were performed in which mice were sacrificed by cervical spine dislocation at specific time points, and their brains were submitted for histological processing. The paraffin-embedded tissues were sectioned at 4 um and stained with hematoxylin and eosin. The site of injection into the fight cerebral hemisphere was easily confirmed at the time of sacrifice because injection was performed under semi-stereotactic guidance.
Immunohistochemical Study
The brains were harvested and embedded in Optimal Cooling Temperature (OCT) compound. The brain tissues were snap-frozen in liquid nitrogen, cut as frozen sections at 4 urn, and placed on plain glass slides. After brief storage at -50~ the slides were air-dried and incubated with the primary mouse IL-2R MAb for 30 minutes at room temperature in a humidified chamber. Subsequently, the sections were washed in PBS for 10 minutes. The fluorescein isothiocyanate-labeled rabbit anti-rat IgG was applied to the sections for 30 minutes.
After the slides were rinsed twice in PBS, coverslips were applied with the use of 90% glycerol in PBS. All sections were then evaluated for the presence or absence of fluorescence ceils in a blinded study by using a fluorescent microscope with epi-illumination optics.
Each antibody was used at optimal concentration as determined by previous titration experiments. As a positive control for IL-2R staining, activated lymphocytes with concanavalin A were prepared in a similar fashion. Negative controls included the use of complete medium containing 10% FCS in place of the primary antibody for brain tissues or the omission of the primary antibody for activated lymphocytes. Negligible background staining was observed.
Results
Kinetics of Anti-IL-2 Antibody and 1L-2 Activity
Prior to the determination of anti-IL-2 antibody activity in test samples, the concentration of enzymelabeled antibodies used in our assay system was optimalized. At the 100-fold dilution of the labeled antibodies, the average absorbance for two dilutions was obtained with the linear range of the reference standard curve (r = 0.998) (Fig. 1) ; the relationship of optical density to the logarithm of the added protein concentration of mouse IgG was almost linear for dilutions of mouse IgG from 80 ng/ml to zero. Therefore, the 100-fold diluted antibodies were used in the following experiments. From this reference curve, it was first confirmed that our assay can function sufficiently to detect the anti-IL-2 antibody activity, and thus the protein concentration of mouse serum was gained in each group of mice after intracerebral or intraperitoneal administration of rIL-2 (Fig. 2) . In our IL-2 antibody detecting system, the titer ofantisera from mice treated with adjuvant agents was much higher than that in mice receiving repeated intracerebral or intraperitoneal infusions to a maximum dose of rIL-2 (80 U/injection/ mouse). It was noted that, while the antibodies were produced in mice treated with multiple intracerebral or intraperitoneal injections of rIL-2 (80 U/injection/ mouse), the titer ofanti-IL-2 antibody was insignificant in other groups with the single administration of rIL-2. Furthermore, it was observed that the a m o u n t of anti-IL-2 antibodies in mice with multiple infusions gradually decreased and reached a plateau in untreated mice 1 month after the last intracerebral injection of rIL-2 (Fig. 3) . In the case of mice treated with a single 80-U infusion of rIL-2, no significant level of anti-IL-2 antibody activity was seen during the 6 weeks after administration (Table 1) . It was verified by double-antibody sandwich EIA that IL-2 activity in the sera was not augmented significantly within 8 weeks following the direct intracerebral administration of rIL-2 (Fig. 4) . In contrast, it was found that the IL-2 activity in serum definitely increased at 3 and 15 minutes after the intravenous infusion of rIL-2, although no significant IL-2 activity was seen at 30 minutes or later.
Histological Examination of Brain Tissues
As c o m p a r e d with sham control experiments using purified mouse albumin injections, the mice treated with rIL-2 in all intracerebral infusion groups did not show any specific in vivo abnormality during the 8 weeks after single or multiple injections. Histological study mainly focused on examining specific changes involving neuronal degeneration or necrosis, stromal necrotizing angiitis and tissue edema, the appearance of a b n o r m a l cells with neovascularization, leptomeningeal or choroid plexus inflammatory reactions, and glial alterations. Although hemorrhages due to direct infusions, thickening of arachnoid membranes, reactive gliosis, or infiltration o f m o n o n u c l e a r lymphoid cells were occasionally seen at the injected sites or subependymal layers (Fig. 5) , neuronal and vascular pathological changes were not induced following intracranial rIL-2 administration. In addition, ventricular dilatation was observed in only a few cases, probably due to intraventricular hemorrhages after the injections. It seems likely, however, that these findings are nonspecific responses
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because of a similar observation in the sham control experiments. The nonspecific reactive changes mostly disappeared within 2 months after intracerebral infusion. Thus, it was suggested that neither specific nor toxic pathological alteration in the normal brain tissues was produced during the 2 months following direct intracerebral administration of rIL-2. The pathological results are summarized in Table 2 .
Immunohistochemical Analysis of Cell-Surface IL-2 Receptor Expression
The expression of IL-2R on the cell surface of brain tissues in mice was compared before and at 1, 2, and 3 weeks after single or multiple intracerebral infusions of the maximum dose of rIL-2 (80 U/injection/mouse), by using immunofluorescence techniques with antimouse IL-2R MAb. No significant expression of IL-2R was induced in either the rlL-2-injected groups or the sham control groups, whereas mitogen-stimulated lymphocytes were clearly stained by the MAb against mouse IL-2R (Fig. 6 ).
Discussion
The authors have previously investigated the therapeutic possibility of specific adoptive immunotherapy with immune cytotoxic T lymphocytes (CTL's) expanded in IL-2 for malignant gliomas. 35"37 It was suggested that the simultaneous administration of IL-2 during adoptive immunotherapy would be more desir- Prior to clinical trials of therapy with combined tumor-specific CTL's and alL-2, the present study was conducted to further analyze the production of anti-IL-2 antibodies in serum, histological changes, and cellsurface expression of IL-2R within the injected mouse brain tissues during the 8 weeks after direct intracerebral administration of rlL-2. The levels of anti-IL-2 antibody activity were found to be lower in mice treated with multiple intracerebral injections of the maximum rlL-2 dose (80 U/injection/mouse) than in those receiving intraperitoneal infusions; however, the levels were insignificant in mice with single intracerebral or intraperitoneal rlL-2 infusions. The explanation for the incomplete production of antibodies in mice receiving repeated intracerebral injections is probably that the immunological reactions cannot be fully generated in the brain, because the brain is considered a partially immunologically privileged environment in which normal regulatory restraints are lacking. 3'17'34 Another explanation is that the BBB in some areas of the injected brain tissues may be artificially destroyed by the direct intracerebral infusion of rlL-2 per se, and therefore systemic immunological responses may be partially induced to produce the antibodies.
In addition to the pharmacokinetics of anti-IL-2 antibody production, we were also interested in the chronological change in IL-2 activity itself following intracerebral injection of rlL-2. Recently, EIA based on the ELISA or radioimmunoassay technique has been developed for quantification of IL-2 using highly purified monoclonal IL-2 antibodies or IL-2. ~8 In lower concentrations, IL-2 has been detected by means of a linear dose-response relationship. In this study, both highly purified capture and indicator IL-2 antibodies were employed for the purpose of catching IL-2 in the test samples. The double-antibody sandwich EIA, which showed as much as 100 times higher sensitivity than a conventional assay, could detect IL-2 activity in concentrations as low as 30 pg/ml with good correlation (r = 0.998) to a bioassay. ~8 The assay also detected native IL-2 in serum. With the use of these assay techniques, it was found that the IL-2 activity in mouse serum did not rise significantly after intracerebral injections of rlL-2. In contrast, a high level of IL-2 activity was seen in mice treated with intravenous infusion of rlL-2.
Concerning the fate of endogenous IL-2 or of IL-2 injected intravenously, it has been determined that the serum half-life of IL-2 is approximately 3 and 6 minutes in mice and humans, respectively, and that IL-2 is primarily cleared from the circulation by the kidney.-'.5.14.19 Pathological examination showed no direct toxic action of rlL-2 on normal brain tissues, although a temporary, nonspecific infiltration of mononuclear lymphoid cells or a reactive gliosis was occasionally observed at the injected site. These nonspecific reactions, however, mostly disappeared within 2 months after intracerebral rlL-2 infusion. In view of the importance of rlL-2 in therapeutic trials as well as in the pathological situation, it was also important to ascertain the presence or absence of IL-2R on the cell surface of normal brain tissues, and to investigate the possibility of IL-2R induction after the injection of rlL-2. The current immunohistochemical analysis suggested that the expression of IL-2R was not enhanced on the cell surface of normal parenchymal brain tissues after intracerebral infusion of rlL-2.
In association with lymphokines, especially interleukin-1 (IL-I) "and IL-2 in the brain, it has been indicated that IL-1 is a potent factor for astroglia proliferation but has no effect on oligodendroglia and that IL-2 does not alter the growth of either type of glial cells. 7'6 Benveniste, et aL, ~ reported that rIL-2 can influence the growth of oligodendrocytes, specifically their proliferation and maturation, but does not affect astrocytes. Furthermore, they have reported that oligodendrocytes can functionally absorb IL-2, although it is unknown whether IL-2 acts on oligodendrocytes via the same type of cell-surface receptor as that required to activate T cells and B cells. Conversely, Saneto, et al., 29 have demonstrated that when IL-1 was added together with IL-2, IL-2 inhibited the proliferation of neonatal rat oligodendrocyte progenitor cells. The action of IL-2 was specifically mediated by the IL-2R. These discrepancies may be a result of different culture conditions, isolation procedures, and the age of the cells tested. With specific reference to IL-2R expression, a recent study by Hofman, eta/., 9 has shown that IL-2R was not determined on the cell surface of normal brain and astrocytoma tissues in humans. This immunohistochemical investigation is consistent with our present results.
From our current basic study, we can conclude that rlL-2 may be safely used for direct administration into the brain. In addition to pharmacological, physiological, and pathological examinations after direct intracerebral administration of rlL.-2, further efforts will be devoted to evaluate the importance of in vivo antitumor efficacy of combined immunotherapy with CTL lines and rlL-2 for malignant gliomas.
